{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:31:37Z","timestamp":1785443497349,"version":"3.56.0"},"reference-count":162,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.vaccine.2015.06.073","type":"journal-article","created":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T22:43:19Z","timestamp":1443739399000},"page":"D46-D54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"S4","title":["Enhancing vaccine safety capacity globally: A lifecycle perspective"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3094-8367","authenticated-orcid":false,"given":"Robert T.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom T.","family":"Shimabukuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick L.F.","family":"Zuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Weibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Sturkenboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9788","key":"10.1016\/j.vaccine.2015.06.073_bib0805","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(11)60766-6","article-title":"A call to action for the new decade of vaccines","volume":"378","author":"Moxon","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2015.06.073_bib0810","first-page":"153","article-title":"Measles outbreak \u2013 California, December 2014\u2013February 2015","volume":"64","author":"Zipprich","year":"2015","journal-title":"MMWR Morb Mort Wkl Report"},{"issue":"9103","key":"10.1016\/j.vaccine.2015.06.073_bib0815","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(97)11096-0","article-title":"Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children","volume":"351","author":"Wakefield","year":"1998","journal-title":"Lancet"},{"issue":"9713","key":"10.1016\/j.vaccine.2015.06.073_bib0820","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0140-6736(10)60175-4","article-title":"Retraction \u2013 Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children","volume":"375","year":"2010","journal-title":"Lancet"},{"issue":"29","key":"10.1016\/j.vaccine.2015.06.073_bib0825","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1016\/j.vaccine.2014.04.085","article-title":"Vaccines are not associated with autism: an evidence-based meta-analysis of case\u2013control and cohort studies","volume":"32","author":"Taylor","year":"2014","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2015.06.073_bib0830","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1542\/peds.2014-1079","article-title":"Safety of vaccines used for routine immunization of U.S. children: a systematic review","volume":"134","author":"Maglione","year":"2014","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.vaccine.2015.06.073_bib0835","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1542\/peds.2014-2715","article-title":"Geographic clusters in under immunization and vaccine refusal","volume":"135","author":"Lieu","year":"2015","journal-title":"Pediatrics"},{"issue":"9099","key":"10.1016\/j.vaccine.2015.06.073_bib0840","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0140-6736(97)04334-1","article-title":"Impact of anti-vaccine movements on pertussis control: the untold story","volume":"351","author":"Gangarosa","year":"1998","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2015.06.073_bib0845","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jcv.2009.07.024","article-title":"Hepatitis B vaccination and French Society ten years after the suspension of the vaccination campaign: how should we raise infant immunization coverage rates?","volume":"46","author":"Balinska","year":"2009","journal-title":"J Clin Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2015.06.073_bib0850","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0040073","article-title":"What led to the Nigerian boycott of the polio vaccination campaign?","volume":"4","author":"Jegede","year":"2007","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.vaccine.2015.06.073_bib0855","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1473-3099(13)70238-X","article-title":"Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action","volume":"14","author":"Barker","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2015.06.073_bib0860","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1016\/j.vaccine.2015.04.034","article-title":"Vaccine Special Issue on Vaccine Hesitancy","volume":"33","author":"Hickler","year":"2015","journal-title":"Vaccine"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2015.06.073_bib0865","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1542\/peds.2010-1722U","article-title":"Editors' introduction: vaccine safety throughout the product life cycle","volume":"127","author":"Salmon","year":"2011","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.vaccine.2015.06.073_bib0870","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0264-410X(94)90315-8","article-title":"The Vaccine Adverse Event Reporting System (VAERS)","volume":"12","author":"Chen","year":"1994","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.vaccine.2015.06.073_bib0875","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJM196911272812205","article-title":"Routine childhood vaccination against smallpox reconsidered","volume":"281","author":"Lane","year":"1969","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.06.073_bib0880","series-title":"Smallpox and its eradication","author":"Fenner","year":"1988"},{"issue":"RR-5","key":"10.1016\/j.vaccine.2015.06.073_bib0885","first-page":"1","article-title":"Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"49","author":"Prevots","year":"2000","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"10.1016\/j.vaccine.2015.06.073_bib0890","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1586\/14760584.2015.1001750","article-title":"Polio endgame: the global introduction of inactivated polio vaccine","volume":"14","author":"Patel","year":"2015","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2015.06.073_bib0895","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1542\/peds.82.2.264","article-title":"National childhood vaccine injury compensation act","volume":"82","author":"Smith","year":"1988","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.vaccine.2015.06.073_bib0900","doi-asserted-by":"crossref","first-page":"e1716","DOI":"10.1542\/peds.2012-3836","article-title":"Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers","volume":"131","author":"Klein","year":"2013","journal-title":"Pediatrics"},{"issue":"RR-16","key":"10.1016\/j.vaccine.2015.06.073_bib0905","first-page":"1","article-title":"Recommendations of the International Task Force for Disease Eradication","volume":"42","year":"1993","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2015.06.073_bib0910","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1469-8749.2010.03781.x","article-title":"Pertussis vaccine encephalopathy: 'Oh! Let us never, never doubt'\u2026","volume":"52","author":"Baxter","year":"2010","journal-title":"Dev Med Child Neurol"},{"issue":"2","key":"10.1016\/j.vaccine.2015.06.073_bib0915","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1353\/pbm.0.0010","article-title":"The first pharmacoepidemiologic investigations: national drug safety policy in the United States, 1901\u20131902","volume":"51","author":"Lilienfeld","year":"2008","journal-title":"Perspect Biol Med"},{"key":"10.1016\/j.vaccine.2015.06.073_bib0920","series-title":"Vaccines","first-page":"1427","article-title":"Regulation and testing of vaccines","author":"Baylor","year":"2012"},{"key":"10.1016\/j.vaccine.2015.06.073_bib0925","series-title":"Vaccine analysis: strategies, principles, and control","author":"Nunnally","year":"2014"},{"key":"10.1016\/j.vaccine.2015.06.073_bib0930","first-page":"4307","article-title":"Current Good Manufacturing Practice Requirements for Combination Products","author":"U.S. Food and Drug Administration (FDA). 21 CFR Part 4 [Docket No. FDA-2009-N-0435]","year":"2013","journal-title":"Federal Register"},{"key":"10.1016\/j.vaccine.2015.06.073_bib0935","series-title":"Guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines. EMA\/CHMP\/VWP\/141697\/2009 ed","author":"Committee for Medicinal Product for Human Use (CHMP)","year":"2010"},{"issue":"993","key":"10.1016\/j.vaccine.2015.06.073_bib0940","first-page":"63","article-title":"WHO Expert Committee on Biological Standardization","author":"WHO","year":"2015","journal-title":"World Health Organ Tech Rep Ser"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2015.06.073_bib0945","doi-asserted-by":"crossref","first-page":"B163","DOI":"10.1016\/j.vaccine.2012.10.117","article-title":"A global regulatory science agenda for vaccines","volume":"31","author":"Elmgren","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.073_bib0950","series-title":"CBER Strategic Plan for Regulatory Science and Research","author":"U.S. Food and Drug Administration (FDA)","year":"2012"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2015.06.073_bib0955","doi-asserted-by":"crossref","first-page":"B176","DOI":"10.1016\/j.vaccine.2012.11.060","article-title":"Developing Countries Vaccine Manufacturers Network: doing good by making high-quality vaccines affordable for all","volume":"31","author":"Pagliusi","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.073_bib0960","series-title":"Vaccines","first-page":"1454","article-title":"Regulation of vaccines in developing countries","author":"Belgharbi","year":"2012"},{"key":"10.1016\/j.vaccine.2015.06.073_bib0965","series-title":"Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials","author":"U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research","year":"2007"},{"issue":"47","key":"10.1016\/j.vaccine.2015.06.073_bib0970","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1016\/j.vaccine.2013.02.041","article-title":"Template protocol for clinical trials investigating vaccines \u2013 focus on safety elements","volume":"31","author":"Bonhoeffer","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2015.06.073_bib0975","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.vaccine.2014.09.035","article-title":"The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)","volume":"33","author":"Chen","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2015.06.073_bib0980","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.vaccine.2014.10.004","article-title":"Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk\/benefit assessment","volume":"33","author":"Monath","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.073_bib0985","series-title":"Pharmacoepidemiology","first-page":"423","article-title":"Pharmacoepidemiology studies of vaccine safety","author":"Chen","year":"2012"},{"issue":"Suppl. 4","key":"10.1016\/j.vaccine.2015.06.073_bib0990","doi-asserted-by":"crossref","first-page":"S323","DOI":"10.1086\/322568","article-title":"Perspectives on the design and analysis of prelicensure trials: bridging the gap to postlicensure studies","volume":"33","author":"Black","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"42","key":"10.1016\/j.vaccine.2015.06.073_bib0995","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1016\/j.vaccine.2014.07.073","article-title":"The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety","volume":"32","author":"McNeil","year":"2014","journal-title":"Vaccine"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2015.06.073_bib1000","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/pds.2323","article-title":"The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise","volume":"21","author":"Nguyen","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2015.06.073_bib1005","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1542\/peds.2010-1722J","article-title":"Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network","volume":"127","author":"LaRussa","year":"2011","journal-title":"Pediatrics"},{"key":"#cr-split#-10.1016\/j.vaccine.2015.06.073_bib1010.1","unstructured":"U.S. Food and Drug Administration. Guidance for Industry: Postmarketing Studies and Clinical Trials - Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act 2011 [updated April 2011"},{"key":"#cr-split#-10.1016\/j.vaccine.2015.06.073_bib1010.2","unstructured":"cited 2015 August 11]. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM172001.pdf."},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2015.06.073_bib1015","doi-asserted-by":"crossref","first-page":"A68","DOI":"10.1016\/j.vaccine.2010.02.037","article-title":"The structure, role, and procedures of the U.S. Advisory Committee on Immunization Practices (ACIP)","volume":"28","author":"Smith","year":"2010","journal-title":"Vaccine"},{"key":"#cr-split#-10.1016\/j.vaccine.2015.06.073_bib1020.1","unstructured":"U.S. Food and Drug Administration (FDA). Charter of the Vaccines and Related Biological Products Advisory Committee 2014 [updated January 9, 2014"},{"key":"#cr-split#-10.1016\/j.vaccine.2015.06.073_bib1020.2","unstructured":"cited 2015 August 11]. Available from: http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/BloodVaccinesandOtherBiologics\/VaccinesandRelatedBiologicalProductsAdvisoryCommittee\/ucm129571.htm."},{"key":"#cr-split#-10.1016\/j.vaccine.2015.06.073_bib1025.1","unstructured":"U.S. Food and Drug Administration (FDA). Charter of the Pediatric Advisory Committee to the Food and Drug Administration 2014 [updated September 18, 2014"},{"key":"#cr-split#-10.1016\/j.vaccine.2015.06.073_bib1025.2","unstructured":"cited 2015 August 11]. Available from: http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/PediatricAdvisoryCommittee\/ucm116525.htm."},{"issue":"Suppl.","key":"10.1016\/j.vaccine.2015.06.073_bib1030","first-page":"20","article-title":"The role of public health informatics in enhancing public health surveillance","volume":"61","author":"Savel","year":"2012","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1035","series-title":"National Vaccine Advisory Committee meeting September 9, 2014: National Vaccine Program Office\/HHS","article-title":"The Vaccine Adverse Event Reporting System (VAERS) form Version 2.0 (proposed)","author":"Shimabukuro","year":"2014"},{"issue":"226","key":"10.1016\/j.vaccine.2015.06.073_bib1040","first-page":"69853","article-title":"Request for Comment on Draft Vaccine Adverse Event Reporting System (VAERS) 2.0 Form","volume":"79","author":"U.S. Centers for Disease Control and Prevention (CDC). [Docket No. CDC-2014-0015]","year":"2014","journal-title":"Federal Register"},{"issue":"111","key":"10.1016\/j.vaccine.2015.06.073_bib1045","first-page":"33072","article-title":"Postmarketing Safety Reports for Human Drug and Biological Products; Electronic Submission Requirements","volume":"79","author":"U.S. Food and Drug Administration (FDA). 21 CFR Parts 310, 314, 329, and 600. [Docket No. FDA-2008-N-0334]. RIN 9010-AF96","year":"2014","journal-title":"Federal Register"},{"issue":"111","key":"10.1016\/j.vaccine.2015.06.073_bib1050","first-page":"33200","article-title":"Draft Guidance for Industry on Providing Submissions in Electronic Format-Postmarketing Safety Reports","volume":"79","author":"U.S. Food and Drug Administration (FDA). [Docket No. FDA-2001-D-0067 (Formerly Docket No. 2001D-0185)]","year":"2014","journal-title":"Federal Register"},{"issue":"6","key":"10.1016\/j.vaccine.2015.06.073_bib1055","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1197\/jamia.M2232","article-title":"Using electronic medical records to enhance detection and reporting of vaccine adverse events","volume":"14","author":"Hinrichsen","year":"2007","journal-title":"J Am Med Inform Assoc"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1060","series-title":"Adult and Pediatric Vaccines at IDWeek 2013; October 3, 2013","article-title":"Automated Detection and Reporting of Vaccine Adverse Events: ESP-VAERS","author":"Baker","year":"2013"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1065","series-title":"Small Business Innovation Research\/Small Business Technology Transfer","author":"Vaccine Adverse Event Reporting System (VAERS) Application for Mobile Devices","year":"2013"},{"issue":"3","key":"10.1016\/j.vaccine.2015.06.073_bib1070","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1001\/jamapediatrics.2013.4469","article-title":"Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine","volume":"168","author":"Stockwell","year":"2014","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1075","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am Stat"},{"issue":"6","key":"10.1016\/j.vaccine.2015.06.073_bib1080","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"issue":"7","key":"10.1016\/j.vaccine.2015.06.073_bib1085","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40264-013-0051-9","article-title":"Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010\u20132011 seasonal influenza virus vaccine","volume":"36","author":"Martin","year":"2013","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.vaccine.2015.06.073_bib1090","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1197\/jamia.M3028","article-title":"Active computerized pharmacovigilance using natural language processing, statistics, and electronic health records: a feasibility study","volume":"16","author":"Wang","year":"2009","journal-title":"J Am Med Inform Assoc"},{"issue":"6","key":"10.1016\/j.vaccine.2015.06.073_bib1095","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/amiajnl-2012-000881","article-title":"Vaccine adverse event text mining system for extracting features from vaccine safety reports","volume":"19","author":"Botsis","year":"2012","journal-title":"J Am Med Inform Assoc"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2015.06.073_bib1100","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1542\/peds.2010-1722H","article-title":"The Vaccine Safety Datalink: a model for monitoring immunization safety","volume":"127","author":"Baggs","year":"2011","journal-title":"Pediatrics"},{"issue":"10 Suppl. 2","key":"10.1016\/j.vaccine.2015.06.073_bib1105","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1097\/MLR.0b013e3180616c0a","article-title":"Real-time vaccine safety surveillance for the early detection of adverse events","volume":"45","author":"Lieu","year":"2007","journal-title":"Med Care"},{"issue":"27","key":"10.1016\/j.vaccine.2015.06.073_bib1110","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1016\/j.vaccine.2012.04.040","article-title":"An efficient statistical algorithm for a temporal scan statistic applied to vaccine safety analyses","volume":"30","author":"McClure","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2015.06.073_bib1115","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/aje\/kwp345","article-title":"Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project","volume":"171","author":"Greene","year":"2010","journal-title":"Am J Epidemiol"},{"issue":"11","key":"10.1016\/j.vaccine.2015.06.073_bib1120","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/j.vaccine.2012.01.027","article-title":"Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010\u20132011","volume":"30","author":"Tse","year":"2012","journal-title":"Vaccine"},{"issue":"46","key":"10.1016\/j.vaccine.2015.06.073_bib1125","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1016\/j.vaccine.2011.08.106","article-title":"Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink","volume":"29","author":"Gee","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2015.06.073_bib1130","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amepre.2011.04.004","article-title":"H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project","volume":"41","author":"Lee","year":"2011","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1135","series-title":"Mini-Sentinel Cber\/Prism Methods Protocol: Pilot Of Self-Controlled Tree-Temporal Scan Analysis For Gardasil Vaccine, Version 2.0","author":"Yih","year":"2015"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1140","series-title":"Clinical Classifications Software: Healthcare Cost and Utilization Project (HCUP)","author":"HCUP","year":"2015"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1145","series-title":"TreeScan: Software for the Tree-Based Scan Statistic","author":"Kulldorff","year":"2014"},{"issue":"5","key":"10.1016\/j.vaccine.2015.06.073_bib1150","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/pds.3423","article-title":"Drug safety data mining with a tree-based scan statistic","volume":"22","author":"Kulldorff","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.vaccine.2015.06.073_bib1155","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ogc.2014.08.001","article-title":"Maternal immunization to benefit the mother, fetus, and infant","volume":"41","author":"Swamy","year":"2014","journal-title":"Obstet Gynecol Clin North Am"},{"issue":"30","key":"10.1016\/j.vaccine.2015.06.073_bib1160","doi-asserted-by":"crossref","first-page":"818","DOI":"10.15585\/mmwr.mm6430a3","article-title":"Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza Season","volume":"64","author":"Grohskopf","year":"2015","journal-title":"MMWR Morbidity and mortality weekly report"},{"issue":"7","key":"10.1016\/j.vaccine.2015.06.073_bib1165","first-page":"131","article-title":"Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012","volume":"62","author":"U.S. Centers for Disease Control Prevention (CDC)","year":"2013","journal-title":"MMWR Morbidity and mortality weekly report"},{"issue":"52","key":"10.1016\/j.vaccine.2015.06.073_bib1170","doi-asserted-by":"crossref","first-page":"7057","DOI":"10.1016\/j.vaccine.2014.09.052","article-title":"Safety of immunization during pregnancy: a review of the evidence of selected inactivated and live attenuated vaccines","volume":"32","author":"Keller-Stanislawski","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1175","article-title":"Maternal influenza immunization and birth outcomes of stillbirth and spontaneous abortion: a systematic review and meta-analysis","author":"Bratton","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"18","key":"10.1016\/j.vaccine.2015.06.073_bib1180","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1001\/jama.2014.14825","article-title":"Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes","volume":"312","author":"Kharbanda","year":"2014","journal-title":"J Am Med Assoc"},{"issue":"3","key":"10.1016\/j.vaccine.2015.06.073_bib1185","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.siny.2013.11.014","article-title":"Vaccines and pregnancy: past, present, and future","volume":"19","author":"Rasmussen","year":"2014","journal-title":"Semin Fetal Neonatal Med"},{"issue":"1","key":"10.1016\/j.vaccine.2015.06.073_bib1190","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/humupd\/dmu041","article-title":"Maternal vaccination: moving the science forward","volume":"21","author":"Faucette","year":"2015","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1195","series-title":"Pregnancy and Lactation Labeling Final Rule","author":"U.S. Food and Drug Administration (FDA)","year":"2014"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1200","series-title":"Draft Guidance for Industry: Pregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological Products","author":"U.S. Food and Drug Administration (FDA)","year":"2014"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1205","series-title":"The Childhood Immunization Schedule and Safety: Stakeholder Concerns, Scientific Evidence, and Future Studies","author":"Institute of Medicine (IOM)","year":"2013"},{"issue":"34","key":"10.1016\/j.vaccine.2015.06.073_bib1210","first-page":"741","article-title":"National, state, and selected local area vaccination coverage among children aged 19\u201335 months \u2013 United States, 2013","volume":"63","author":"Elam-Evans","year":"2014","journal-title":"MMWR Morb Mort Wkl Report"},{"issue":"3","key":"10.1016\/j.vaccine.2015.06.073_bib1215","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1001\/jamapediatrics.2013.502","article-title":"A population-based cohort study of under vaccination in 8 managed care organizations across the United States","volume":"167","author":"Glanz","year":"2013","journal-title":"JAMA Pediatr"},{"issue":"6","key":"10.1016\/j.vaccine.2015.06.073_bib1220","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMra1204186","article-title":"Designing tomorrow's vaccines","volume":"368","author":"Nabel","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2015.06.073_bib1225","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1586\/erv.11.21","article-title":"Trends in vaccine adjuvants","volume":"10","author":"Schijns","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2015.06.073_bib1230","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4103\/2230-973X.82384","article-title":"Recent trends in vaccine delivery systems: a review","volume":"1","author":"Saroja","year":"2011","journal-title":"Int J Pharm Investig"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1235","first-page":"369","article-title":"Microneedle-based vaccines","volume":"333","author":"Prausnitz","year":"2009","journal-title":"Curr Top Microbiol Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2015.06.073_bib1240","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4161\/hv.7.1.13739","article-title":"Sublingual vaccination","volume":"7","author":"Czerkinsky","year":"2011","journal-title":"Hum Vaccin"},{"issue":"6","key":"10.1016\/j.vaccine.2015.06.073_bib1245","first-page":"1","article-title":"Systems biology as defined by NIH: an intellectual resource for integrative biology","volume":"19","author":"Wanjek","year":"2011","journal-title":"NIH Catal"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1250","unstructured":"U.S. National Institutes of Health (NIH). Talking Glossary of Genetic Terms: Personalized Medicine. National Human Genome Research Institute. Available from: http:\/\/www.genome.gov\/glossary\/index.cfm?id=150."},{"issue":"9","key":"10.1016\/j.vaccine.2015.06.073_bib1255","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1089\/omi.2011.0012","article-title":"The top five ``game changers'' in vaccinology: toward rational and directed vaccine development","volume":"15","author":"Kennedy","year":"2011","journal-title":"OMICS"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1260","series-title":"Paving the Way for Personalized Medicine: FDA's Role in a New Era of Medical Product Development","author":"U.S. Food and Drug Administration (FDA)","year":"2013"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1265","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2015.04.088","article-title":"Lessons learned in the analysis of high-dimensional data in vaccinomics","author":"Oberg","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1270","unstructured":"Remarks by the President in State of the Union Address, January, 20, 2015. 2015. [cited 2015 August 11]. Available from: http:\/\/www.whitehouse.gov\/the-press-office\/2015\/01\/20\/remarks-president-state-union-address-january-20-2015."},{"key":"10.1016\/j.vaccine.2015.06.073_bib1275","series-title":"Facilitators Report, Lessons learned exercise, ECDC Vaccine Adverse Event Surveillance and Communication: (VAESCO II) project","author":"Destefano","year":"2009"},{"issue":"6","key":"10.1016\/j.vaccine.2015.06.073_bib1280","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/joim.12159","article-title":"Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?","volume":"275","author":"Trifiro","year":"2014","journal-title":"J Intern Med"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1285","doi-asserted-by":"crossref","first-page":"d3908","DOI":"10.1136\/bmj.d3908","article-title":"Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe","volume":"343","author":"Dieleman","year":"2011","journal-title":"Br Med J"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1290","series-title":"Narcolepsy in association with pandemic influenza vaccination \u2013 a multi-country European epidemiological investigation","author":"European Centre for Disease Prevention and Control (ECDC)","year":"2012"},{"issue":"8","key":"10.1016\/j.vaccine.2015.06.073_bib1295","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.vaccine.2012.12.015","article-title":"The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns","volume":"31","author":"Wijnans","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2015.06.073_bib1300","doi-asserted-by":"crossref","first-page":"e82222","DOI":"10.1371\/journal.pone.0082222","article-title":"Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe","volume":"9","author":"Romio","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1305","series-title":"Vaccines","first-page":"1369","article-title":"Immunization in developing countries","author":"Mitchell","year":"2013"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2015.06.073_bib1310","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0264-410X(98)00246-1","article-title":"The introduction of new vaccines into developing countries","volume":"17","author":"Mahoney","year":"1999","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2015.06.073_bib1315","doi-asserted-by":"crossref","first-page":"436","DOI":"10.2471\/BLT.13.133298","article-title":"Impact of BRICS' investment in vaccine development on the global vaccine market","volume":"92","author":"Kaddar","year":"2014","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1320","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2217\/phe.09.25","article-title":"Global trends and challenges in vaccine safety","volume":"3","author":"Black","year":"2009","journal-title":"Pediatric Health"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1325","series-title":"Global Vaccine Safety Blueprint Geneva","author":"World Health Organization (WHO)","year":"2012"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1330","unstructured":"World Health Organization (WHO). The Global Vaccine Safety Initiative (GVSI) WHO. Available from: http:\/\/www.who.int\/vaccine_safety\/initiative\/en\/ [updated November 2014]."},{"issue":"9","key":"10.1016\/j.vaccine.2015.06.073_bib1335","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2471\/BLT.14.138875","article-title":"The Global Vaccine Safety Initiative: enhancing vaccine pharmacovigilance capacity at country level","volume":"92","author":"Maure","year":"2014","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1340","series-title":"Global Vaccine Safety Initiative portfolio of activities Switzerland","author":"World Health Organization (WHO)","year":"2013"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1345","series-title":"Global Vaccine Safety Blueprint: The Landscape Analysis Geneva","author":"World Health Organization (WHO)","year":"2012"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1350","series-title":"Strengthening national regulatory authorities","author":"World Health Organization (WHO)","year":"2012"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1355","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ599","article-title":"Lessons learnt from enhancing vaccine pharmacovigilance activities during MenAfriVac\u2122 introduction in African countries, 2010 to 2013","author":"Diomande","year":"2015","journal-title":"CID"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1360","first-page":"18","article-title":"Global Advisory Committee on Vaccine Safety: Preparing for malaria vaccine introduction","volume":"90","author":"World Health Organization (WHO)","year":"2015","journal-title":"Wkly Epid Rec"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1365","first-page":"17","article-title":"Global Advisory Committee on Vaccine Safety: Preparing for dengue vaccine introduction","volume":"90","author":"World Health Organization (WHO)","year":"2015","journal-title":"Wkly Epid Rec"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1370","article-title":"An Ebola vaccine: first results and promising opportunities","author":"The Lancet","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1375","unstructured":"Council for International Organizations of Medical Sciences (CIOMS), 2013. Available from: http:\/\/www.cioms.ch\/."},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2015.06.073_bib1380","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2013.02.035","article-title":"Decade of vaccines. Editorial","volume":"31","author":"Alonso","year":"2013","journal-title":"Vaccine"},{"issue":"35","key":"10.1016\/j.vaccine.2015.06.073_bib1385","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1016\/j.vaccine.2013.05.027","article-title":"Roadmap for the international collaborative epidemiologic monitoring of safety and effectiveness of new high priority vaccines","volume":"31","author":"Izurieta","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1390","unstructured":"Indepth Network, Better Health Information for Better Health Policy, Available from: http:\/\/www.indepth-network.org\/."},{"issue":"40","key":"10.1016\/j.vaccine.2015.06.073_bib1395","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1016\/j.vaccine.2013.06.032","article-title":"International collaboration to assess the risk of Guillain Barre Syndrome following Influenza A (H1N1) 2009 monovalent vaccines","volume":"31","author":"Dodd","year":"2013","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2015.06.073_bib1400","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.vaccine.2009.11.034","article-title":"Developing sustainable funding for vaccine safety infrastructure","volume":"28","author":"Black","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1405","series-title":"The Jordan report: accelerated development of vaccines 2012","author":"U.S. National Institutes of Health (NIH)","year":"2012"},{"issue":"34","key":"10.1016\/j.vaccine.2015.06.073_bib1410","doi-asserted-by":"crossref","first-page":"12288","DOI":"10.1073\/pnas.1402981111","article-title":"Vaccines, new opportunities for a new society","volume":"111","author":"Rappuoli","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.vaccine.2015.06.073_bib1415","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2471\/BLT.07.040089","article-title":"Vaccination greatly reduces disease, disability, death and inequity worldwide","volume":"86","author":"Andre","year":"2008","journal-title":"Bull World Health Organ"},{"issue":"5","key":"10.1016\/j.vaccine.2015.06.073_bib1420","doi-asserted-by":"crossref","first-page":"800","DOI":"10.2105\/AJPH.2004.039438","article-title":"Evaluating the safety of new vaccines: summary of a workshop","volume":"95","author":"Ellenberg","year":"2005","journal-title":"Am J Public Health"},{"issue":"8","key":"10.1016\/j.vaccine.2015.06.073_bib1425","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.4161\/hv.25085","article-title":"The rise (and fall?.) of parental vaccine hesitancy","volume":"9","author":"Gowda","year":"2013","journal-title":"Hum Vaccines Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2015.06.073_bib1430","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/oxfordjournals.aje.a114471","article-title":"Individual versus public priorities in the determination of optimal vaccination policies","volume":"124","author":"Fine","year":"1986","journal-title":"Am J Epidemiol"},{"issue":"11","key":"10.1016\/j.vaccine.2015.06.073_bib1435","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/01.inf.0000183853.16113.a6","article-title":"Vaccine safety controversies and the future of vaccination programs","volume":"24","author":"Francois","year":"2005","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"10.1016\/j.vaccine.2015.06.073_bib1440","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.4161\/hv.24657","article-title":"Vaccine hesitancy: an overview","volume":"9","author":"Dube","year":"2013","journal-title":"Hum Vaccines Immunother"},{"issue":"16","key":"10.1016\/j.vaccine.2015.06.073_bib1445","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1056\/NEJM198704163161601","article-title":"A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army","volume":"316","author":"Seeff","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1450","first-page":"16","article-title":"The cutter incident, poliomyelitis following formaldehyde- inactivated poliovirus vaccination in the United States during the spring of 1955. I. Background","volume":"78","author":"Nathanson","year":"1963","journal-title":"Am J Hygiene"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1455","first-page":"29","article-title":"The cutter incident, poliomyelitis following formaldehyde- inactivated poliovirus vaccination in the United States during the spring of 1955. II. Relationship of poliomyelitis to cutter vaccine","volume":"78","author":"Nathanson","year":"1963","journal-title":"Am J Hygiene"},{"issue":"14","key":"10.1016\/j.vaccine.2015.06.073_bib1460","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1056\/NEJMp048180","article-title":"The Cutter incident, 50 years later","volume":"352","author":"Offit","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1465","series-title":"The hazards of immunization","first-page":"324","author":"Wilson","year":"1967"},{"issue":"2","key":"10.1016\/j.vaccine.2015.06.073_bib1470","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976\u20131977","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.vaccine.2015.06.073_bib1475","first-page":"1","article-title":"Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) \u2013 United States, 1991\u20132001","volume":"52","author":"Zhou","year":"2003","journal-title":"MMWR Surveill Summ"},{"issue":"3","key":"10.1016\/j.vaccine.2015.06.073_bib1480","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0264-410X(87)90094-6","article-title":"Monitoring system for adverse events following immunization","volume":"5","author":"Stetler","year":"1987","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.vaccine.2015.06.073_bib1485","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJM198606123142427","article-title":"Adverse-drug-reaction monitoring","volume":"314","author":"Faich","year":"1986","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.vaccine.2015.06.073_bib1490","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1016\/S0264-410X(01)00237-7","article-title":"Data mining in the US Vaccine Adverse Event Reporting System (VAERS): early detection of intussusception and other events after rotavirus vaccination","volume":"19","author":"Niu","year":"2001","journal-title":"Vaccine"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2015.06.073_bib1495","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0264-410X(02)00449-8","article-title":"The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI)","volume":"21","author":"Bonhoeffer","year":"2002","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2015.06.073_bib1500","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1542\/peds.99.6.765","article-title":"Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team","volume":"99","author":"Chen","year":"1997","journal-title":"Pediatrics"},{"issue":"3 Part 1","key":"10.1016\/j.vaccine.2015.06.073_bib1505","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1542\/peds.101.3.453","article-title":"Risky business: challenges in vaccine risk communication","volume":"101","author":"Ball","year":"1998","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.vaccine.2015.06.073_bib1510","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/10810730490503487","article-title":"National Immunization Information Hotline: Calls concerning adverse events, 1998\u20132000","volume":"9","author":"Gust","year":"2004","journal-title":"J Health Commun"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1515","series-title":"Adverse Effects of Pertussis and Rubella Vaccines: A Report of the Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines","year":"1991"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1520","series-title":"Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality","year":"1994"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1525","series-title":"Immunization Safety Review 2001\u20132004: National Academy Press (US)","author":"Institute of Medicine (IOM)","year":"2004"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1530","series-title":"Adverse Effects of Vaccines: Evidence and Causality","year":"2011"},{"issue":"8949","key":"10.1016\/j.vaccine.2015.06.073_bib1535","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0140-6736(95)90471-9","article-title":"A new method for active surveillance of adverse events from diphtheria\/tetanus\/pertussis and measles\/mumps\/rubella vaccines","volume":"345","author":"Farrington","year":"1995","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2015.06.073_bib1540","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1586\/14760584.5.5.641","article-title":"Post licensure epidemiology of childhood vaccination: the Danish experience","volume":"5","author":"Hviid","year":"2006","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.06.073_bib1545","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ080","article-title":"Improving vaccine safety through a better understanding of vaccine adverse events","author":"Pasternak","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2015.06.073_bib1550","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/oxfordjournals.aje.a010239","article-title":"Outbreak of aseptic meningitis associated with mass vaccination with a urabe-containing measles-mumps-rubella vaccine: implications for immunization programs","volume":"151","author":"Dourado","year":"2000","journal-title":"Am J Epidemiol"},{"issue":"6","key":"10.1016\/j.vaccine.2015.06.073_bib1555","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.vaccine.2012.11.095","article-title":"Investigation of an outbreak of hypersensitivity-type reactions during the 2004 national measles-mumps-rubella vaccination campaign in Brazil","volume":"31","author":"Freitas","year":"2013","journal-title":"Vaccine"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2015.06.073_bib1560","doi-asserted-by":"crossref","first-page":"B46","DOI":"10.1016\/j.vaccine.2011.12.112","article-title":"Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010","volume":"30","author":"Ouandaogo","year":"2012","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2015.06.073_bib1565","first-page":"787","article-title":"Injection safety: a global challenge","volume":"77","author":"Hutin","year":"1999","journal-title":"Bull World Health Organ"},{"issue":"8","key":"10.1016\/j.vaccine.2015.06.073_bib1570","first-page":"604","article-title":"The use of a computerized database to monitor vaccine safety in Viet Nam","volume":"83","author":"Ali","year":"2005","journal-title":"Bull World Health Organ"},{"issue":"6","key":"10.1016\/j.vaccine.2015.06.073_bib1575","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1542\/peds.110.6.e71","article-title":"Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States","volume":"110","author":"Pool","year":"2002","journal-title":"Pediatrics"},{"issue":"7","key":"10.1016\/j.vaccine.2015.06.073_bib1580","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archfami.9.7.617","article-title":"Does influenza vaccination exacerbate asthma? Analysis of a large cohort of children with asthma. Vaccine Safety Datalink Team","volume":"9","author":"Kramarz","year":"2000","journal-title":"Arch Fam Med"},{"issue":"4","key":"10.1016\/j.vaccine.2015.06.073_bib1585","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/art.24418","article-title":"HLA type and immune response to Borrelia burgdorferi outer surface protein a in people in whom arthritis developed after Lyme disease vaccination","volume":"60","author":"Ball","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.vaccine.2015.06.073_bib1590","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.vaccine.2011.12.118","article-title":"A genomics-based approach to assessment of vaccine safety and immunogenicity in children","volume":"30","author":"White","year":"2012","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2015.06.073_bib1595","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1212\/WNL.34.2.240","article-title":"HLA antigens in Guillain-Barre syndrome","volume":"34","author":"Kaslow","year":"1984","journal-title":"Neurology"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15008749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15008749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T14:24:08Z","timestamp":1718115848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15008749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":162,"alternative-id":["S0264410X15008749"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.06.073","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing vaccine safety capacity globally: A lifecycle perspective","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.06.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Journal of Preventive Medicine. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}